MedPath

The effect of Levetiracetam and phenobarbital in treatment of neonatal seizures

Phase 3
Conditions
Acute neonatal seizure.
Epilepsy and recurrent seizures
Registration Number
IRCT20090412001808N7
Lead Sponsor
Sari University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Term neonates
Age = 28 days
Clinical seizures requiring treatment based on the diagnosis of a neonatalologist
Seizure diagnosis based on pediatric neurologist diagnosis and EEG interpretation
Written informed consent of parents

Exclusion Criteria

Renal failure
Seizures caused by electrolyte disorders such as hypocalcemia and hypoglycemia
Patients whose seizures respond to vitamin B6 administration
Sensitivity to Levetiracetam or phenobarbital
Structure Anomaly
Asphyxia

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Seizure. Timepoint: 30 min, 24 hour up to 1 week, 1st month, 2nd month, 3rd month. Method of measurement: Clinical examination and observation of paroxysmal movements of the neonate.
Secondary Outcome Measures
NameTimeMethod
Sizure recurrence. Timepoint: 30 min, 24 hour up to 1 week, 1st month, 2nd month, 3rd montt. Method of measurement: Clinical examination and observation.
© Copyright 2025. All Rights Reserved by MedPath